MRVI Valuation

Maravai LifeSciences Holdings Inc

Add to Watchlist

Advanced Chart

1.940

-0.160(-7.620%)

Overview
Forecast
Valuation

MRVI Relative Valuation

MRVI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MRVI is overvalued; if below, it's undervalued.

Historical Valuation

Maravai LifeSciences Holdings Inc(MRVI) is now in theUndervaluedzone, suggesting that its currentforward PSratio of1.56is consideredUndervaluedcompared with the five-year average of4.74.The fair price of Maravai LifeSciences Holdings Inc(MRVI)is between19.23to22.44according to relative valuation methord.Compared to the current price of1.94USD, Maravai LifeSciences Holdings Inc isUndervalued By 89.91%.

Relative Value

Fair Zone

19.23-22.44

Current Price：1.94

89.91%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.85

P/B

Median3y

3.73

Median5y

10.06

-7.36

FCF Yield

Median3y

11.61

Median5y

9.61

Competitors Valuation Multiple

The average P/S ratio for MRVI's competitors is 56.57, providing a benchmark for relative valuation. Maravai LifeSciences Holdings Inc Corp (MRVI) exhibits a P/S ratio of 1.56, which is -97.23% above the industry average. Given its robust revenue growth of -2.49%, this premium appearsunsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

MRVI.O

Maravai LifeSciences Holdings Inc